Collegium Pharmaceutical Stock Buy Hold or Sell Recommendation
| COLL Stock | USD 28.82 0.37 1.27% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Collegium Pharmaceutical is 'Sell'. The recommendation algorithm takes into account all of Collegium Pharmaceutical's available fundamental, technical, and predictive indicators you will find on this site.
Check out Collegium Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide. Note, we conduct extensive research on individual companies such as Collegium and provide practical buy, sell, or hold advice based on investors' constraints. Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Collegium |
Execute Collegium Pharmaceutical Buy or Sell Advice
The Collegium recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Collegium Pharmaceutical. Macroaxis does not own or have any residual interests in Collegium Pharmaceutical or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Collegium Pharmaceutical's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Collegium Pharmaceutical Trading Alerts and Improvement Suggestions
| Collegium Pharmaceutical generated a negative expected return over the last 90 days | |
| Collegium Pharmaceutical currently holds 674.28 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity. | |
| Over 98.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Rubric Capital Management LP Increases Stake in Collegium Pharmaceutical Inc |
Collegium Pharmaceutical Returns Distribution Density
The distribution of Collegium Pharmaceutical's historical returns is an attempt to chart the uncertainty of Collegium Pharmaceutical's future price movements. The chart of the probability distribution of Collegium Pharmaceutical daily returns describes the distribution of returns around its average expected value. We use Collegium Pharmaceutical price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Collegium Pharmaceutical returns is essential to provide solid investment advice for Collegium Pharmaceutical.
| Mean Return | 0.01 | Value At Risk | -3.32 | Potential Upside | 3.07 | Standard Deviation | 2.61 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Collegium Pharmaceutical historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Collegium Stock Institutional Investors
| Shares | Emerald Advisers, Llc | 2024-12-31 | 811.7 K | Geode Capital Management, Llc | 2024-12-31 | 770.5 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 679.3 K | Massachusetts Financial Services Company | 2024-12-31 | 604.2 K | Emerald Mutual Fund Advisers Trust | 2024-12-31 | 569.6 K | Victory Capital Management Inc. | 2024-12-31 | 559.5 K | Jpmorgan Chase & Co | 2024-09-30 | 554.4 K | Lsv Asset Management | 2024-12-31 | 390.5 K | Northern Trust Corp | 2024-12-31 | 385.2 K | Blackrock Inc | 2024-12-31 | 5.6 M | Eventide Asset Management, Llc | 2024-12-31 | 2.6 M |
Collegium Pharmaceutical Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 6.6M | 12.3M | (12.7M) | 63.8M | 73.3M | 77.0M | |
| Free Cash Flow | (279.8M) | 101.6M | 122.6M | 274.3M | 315.4M | 331.2M | |
| Depreciation | 61.6M | 68.9M | 138.9M | 149.3M | 171.6M | 180.2M | |
| Other Non Cash Items | 9.0M | 3.4M | 8.5M | 30.6M | 35.2M | 37.0M | |
| Capital Expenditures | 373.8M | 1.9M | 1.6M | 461K | 530.2K | 503.6K | |
| Net Income | 26.8M | 71.5M | (25.0M) | 48.2M | 55.4M | 58.1M | |
| End Period Cash Flow | 176.7M | 189.0M | 176.2M | 240.0M | 276.0M | 147.5M | |
| Change To Inventory | (8.3M) | (2.3M) | 48.3M | 14.2M | 16.3M | 17.1M | |
| Change To Netincome | 16.5M | 21.9M | (53.8M) | 14.5M | 13.0M | 13.7M | |
| Investments | (373.8M) | (1.9M) | (573.7M) | (46.7M) | (42.0M) | (44.1M) | |
| Change Receivables | 5.0M | (10.4M) | (22.5M) | (21.8M) | (19.6M) | (20.6M) |
Collegium Pharmaceutical Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Collegium Pharmaceutical or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Collegium Pharmaceutical's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Collegium stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0 | |
β | Beta against Dow Jones | 0.41 | |
σ | Overall volatility | 2.69 | |
Ir | Information ratio | 0 |
Collegium Pharmaceutical Volatility Alert
Collegium Pharmaceutical has relatively low volatility with skewness of 2.57 and kurtosis of 13.36. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Collegium Pharmaceutical's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Collegium Pharmaceutical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Collegium Pharmaceutical Fundamentals Vs Peers
Comparing Collegium Pharmaceutical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Collegium Pharmaceutical's direct or indirect competition across all of the common fundamentals between Collegium Pharmaceutical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Collegium Pharmaceutical or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Collegium Pharmaceutical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Collegium Pharmaceutical to competition |
| Fundamentals | Collegium Pharmaceutical | Peer Average |
| Return On Equity | 0.43 | -0.31 |
| Return On Asset | 0.0968 | -0.14 |
| Profit Margin | 0.15 % | (1.27) % |
| Operating Margin | 0.35 % | (5.51) % |
| Current Valuation | 1.7 B | 16.62 B |
| Shares Outstanding | 32.25 M | 571.82 M |
| Shares Owned By Insiders | 2.16 % | 10.09 % |
| Shares Owned By Institutions | 97.84 % | 39.21 % |
| Number Of Shares Shorted | 5.68 M | 4.71 M |
| Price To Earning | 28.80 X | 28.72 X |
| Price To Book | 4.02 X | 9.51 X |
| Price To Sales | 1.57 X | 11.42 X |
| Revenue | 566.77 M | 9.43 B |
| Gross Profit | 519.33 M | 27.38 B |
| EBITDA | 308.33 M | 3.9 B |
| Net Income | 48.16 M | 570.98 M |
| Cash And Equivalents | 122.72 M | 2.7 B |
| Cash Per Share | 3.60 X | 5.01 X |
| Total Debt | 674.28 M | 5.32 B |
| Debt To Equity | 3.82 % | 48.70 % |
| Current Ratio | 0.99 X | 2.16 X |
| Book Value Per Share | 7.27 X | 1.93 K |
| Cash Flow From Operations | 274.75 M | 971.22 M |
| Short Ratio | 13.12 X | 4.00 X |
| Earnings Per Share | 2.34 X | 3.12 X |
| Target Price | 42.8 | |
| Number Of Employees | 197 | 18.84 K |
| Beta | 0.82 | -0.15 |
| Market Capitalization | 939.45 M | 19.03 B |
| Total Asset | 1.14 B | 29.47 B |
| Retained Earnings | (233.19 M) | 9.33 B |
| Working Capital | 79.69 M | 1.48 B |
| Current Asset | 96.88 M | 9.34 B |
Note: Disposition of 25149 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 30.52 subject to Rule 16b-3 [view details]
Collegium Pharmaceutical Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Collegium . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Collegium Pharmaceutical Buy or Sell Advice
When is the right time to buy or sell Collegium Pharmaceutical? Buying financial instruments such as Collegium Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Collegium Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Collegium Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share | Quarterly Revenue Growth 0.165 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.